Deepika Razia

Deepika Razia

Auto-generated profile, based on publicly available information

Deepika Razia

Department of Medicine, Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, Arizona

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
MCMáté Csucska
Máté Csucska
DRDeepika Razia
Deepika Razia
TMTakahiro Masuda
Takahiro Masuda
AOAshraf Omar
Ashraf Omar
LGLuca M. Giulini
Luca M. Giulini
SMSumeet K. Mittal
Sumeet K. Mittal

29 August 2022 in Transplant Immunology
Verified
Journal Article
Closed access
DRDeepika Razia
Deepika Razia
CHChengcheng Hu
Chengcheng Hu
LCLauren Cherrier
Lauren Cherrier
ANAasya Nasar
Aasya Nasar
RWRajat Walia
Rajat Walia
STSofya Tokman
Sofya Tokman

16 October 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DSDevika Sindu
Devika Sindu
DRDeepika Razia
Deepika Razia
CBCurt Bay
Curt Bay
JPJosna Padiyar
Josna Padiyar
KGKatherine Grief
Katherine Grief
STSofya Tokman
Sofya Tokman

22 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
DRDeepika Razia
Deepika Razia
MOMichael T. Olson
Michael T. Olson
KGKatherine Grief
Katherine Grief
RWRajat Walia
Rajat Walia
RBRoss M. Bremner
Ross M. Bremner
STSofya Tokman
Sofya Tokman
Hospitalized lung transplant (LT) recipients (LTRs) have higher post-LT morbidity and mortality than those who are well enough to wait for transplant at home. Outcomes after LT for COVID-19-associated acute respiratory distress syndrome (CARDS) may be even worse; thus, we compared post-LT outcomes between hospitalized LTRs transplanted for CARDS and those transplanted for restrictive lung disease (RLD). Between 2014 and 2021, hospitalized LTRs ≥18 years old with CARDS or RLD were included. Primary and secondary outcomes were 1-year post-LT survival and postoperative morbidity. For each patient in the CARDS group, an analysis of 1-to-1 matched patients from the RLD group was performed using logistic regression modeling. Of 764 LTRs, 163 (21.3%) were hospitalized at the time of LT; 132 met the inclusion criteria: 11 (8.3%) were transplanted for CARDS and 121 (91.7%) for RLD. LTRs with CARDS were younger with longer pre-LT hospitalization stays and higher rates of pretransplant mechanical ventilation, dialysis, and ECMO as a bridge to transplant. A propensity-matched analysis demonstrated comparable rates of intrathoracic adhesions, posttransplant duration of mechanical ventilation, PGD3 at 72 hours, and delayed chest closure. Compared to LTRs with RLD, those with CARDS had significantly longer posttransplant hospital stays and a higher prevalence of ACR ≥A2 and DSA >2000 MFI, but comparable 1-year survival rates. Even with careful selection, LT for patients with CARDS was associated with significant morbidity; however, 1-year survival of recipients with CARDS was comparable to that of matched hospitalized recipients with RLD.

3 March 2022 in Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DRDeepika Razia
Deepika Razia
STSofya Tokman
Sofya Tokman
SISharjeel Israr
Sharjeel Israr
HMHesham Mohamed
Hesham Mohamed
HAHesham Abdelrazek
Hesham Abdelrazek
AOAshraf Omar
Ashraf Omar
Background. Persistent orthostatic hypotension (OH) is a lesser-known complication of lung transplantation (LTx). In this retrospective case series, we describe the clinical manifestations, complications, and treatment of persistent OH in 13 LTx recipients. Methods. We identified LTx recipients who underwent transplantation between March 1, 2018, and March 31, 2020, with persistent symptomatic OH and retrospectively queried the records for clinical information. Results. Thirteen patients were included in the analysis, 9 (69) had underlying pulmonary fibrosis, and 12 (92) were male. The median age, height, and body mass index at LTx were 68 years, 70 inches, and 27kg/m2, respectively. Six (46) patients were deceased at the time of chart abstraction with a median (IQR) posttransplant survival of 12.6 months (6, 21); the 7 remaining living patients were a median of 19.6 months (18, 32) posttransplant. Signs and symptoms of OH developed a median of 60 (7, 75) days after transplant. Patients were treated with pharmacological agents and underwent extensive physical therapy. Most patients required inpatient rehabilitation (n=10, 77), and patients commonly developed comorbid conditions including weight loss, renal insufficiency with eGFR <50 (n=13, 100), gastroparesis (n=7, 54), and tachycardia-bradycardia syndrome (n=2, 15). Falls were common (n=10, 77). The incidence of OH in LTx recipients at our center during the study period was 5.6 (13/234). Conclusions. Persistent OH is a lesser-known complication of LTx that impacts posttransplant rehabilitation and may lead to comorbidities and shortened survival. In addition, most LTx recipients with OH at our center were tall, thin men with underlying pulmonary fibrosis, which may offer an opportunity to instate pretransplant OH screening of at-risk patients.

11 February 2022 in Transplantation Direct
Verified
Journal Article
Open access
DRDeepika Razia
Deepika Razia
SMSumeet K. Mittal
Sumeet K. Mittal
SBSandhya Bansal
Sandhya Bansal
RRRanjithkumar Ravichandran
Ranjithkumar Ravichandran
MSMichael A. Smith
Michael A. Smith
STSofya Tokman
Sofya Tokman
Background. Pre–lung transplant (LTx) gastroesophageal reflux (GER) and circulating antibodies against the lung self-antigens (SAbs) collagen V and K-alpha-1 tubulin may predispose recipients to chronic lung allograft dysfunction (CLAD). We aimed to study the association of pre-LTx GER or pre-LTx SAbs with CLAD. Methods. In this retrospective analysis of patients who underwent LTx between 2015 and 2019, pre-LTx GER and SAbs were dichotomously defined as present or absent. The study group comprised recipients with either GER‚ SAbs, or both, and the control group comprised recipients without GER or SAbs. Endpoints included CLAD and survival. Results. Ninety-five LTx recipients were divided into a study group (n = 71; 75%) and a control group (n = 24; 25%). Pretransplant GER was associated with pre-LTx SAbs (odds ratio [95% confidence intervals], 5.022 [1.419-17.770]; P = 0.012). In addition, the study group (either GER‚ SAbs, or both) had a higher risk of CLAD (hazard ratio [95% confidence intervals], 8.787 [1.694-45.567]; P = 0.010) and lower CLAD-free survival after LTx than the control group (P = 0.007); however, overall survival was similar between the 2 groups (P = 0.618). Conclusions. GER was associated with elevated SAbs in LTx candidates, and either GER, SAbs, or both were associated with CLAD in LTx recipients. This association suggests that GER may cause an immune response to normally sequestered lung-associated self-antigens that drives ongoing lung injury.